Answers are grounded in this paper and cite their sources.
Low grade serous ovarian cancers (LGSOC) in an advanced setting have limited systemic treatment options. In this paper we report a case of metastatic LGSOC harboring a BRAF mutation, treated with dabrafenib. We discuss the clinical, pathologic and molecular characteristics as well as surgical considerations and ongoing investigations in LGSOC.
No takes yet. Share an insight, caveat, or question.
Sama et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: